Welcome to our dedicated page for Design Therapeutics SEC filings (Ticker: DSGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Design Therapeutics, Inc. filings document the regulatory disclosures of a Nasdaq-listed, clinical-stage biotechnology company developing GeneTAC® small-molecule therapies for serious degenerative genetic diseases. Its 8-K reports furnish financial results, corporate presentations, pipeline updates, and material governance events tied to board appointments, resignations, committee assignments, director compensation, and indemnification arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, stockholder voting procedures, and board structure. The filing record also identifies the company’s common stock registration on The Nasdaq Global Select Market, emerging growth company status, and public-company disclosure framework for operations, capital structure, governance, and risk reporting.
Design Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the April 14, 2026 record date, 62,441,429 shares of common stock were outstanding and entitled to vote.
Stockholders elected Simeon George, M.D. as a Class II director, with 29,205,208 votes for, 7,608,724 votes withheld and 13,264,883 broker non-votes. They also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 50,077,708 votes for, 201 votes against and 906 abstentions.
Design Therapeutics, Inc. reports that Point72-related filers beneficially own 3,197,764 shares of common stock, equal to 5.1% of the class, as of the close of business on June 8, 2026. The disclosure is made on a Schedule 13G and identifies shared voting and dispositive power among Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen.
Design Therapeutics reported new biomarker and clinical data from its ongoing Phase 1/2 RESTORE-FA trial of DT-216P2 in Friedreich ataxia. Sixteen patients received weekly intravenous doses from 0.1 to 1 mpk for four weeks.
At the 1 mpk dose, patients showed mean improvements of 6.4 points on the modified Friedreich’s Ataxia Rating Scale and 2.7 points in the Upright Stability Score. Patient-reported fatigue improved by more than five points on the PROMIS Fatigue Scale at four weeks and two weeks after the last dose, exceeding the three-point minimal important change. Whole blood FXN mRNA increased 65%, FXN-M and FXN-E protein rose 22–27%, and muscle FXN mRNA increased 42%, indicating robust frataxin restoration. DT-216P2 was generally well-tolerated, with only mild to moderate adverse events. The company plans to pursue a registrational path and provide an update in the fourth quarter of 2026.
Design Therapeutics ownership disclosure: Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report 2,722,754 shares of common stock, representing 4.4% of the class as of March 31, 2026. The filing states they hold shared voting and shared dispositive power through investment management arrangements; each Reporting Person directly owns no shares.
Design Therapeutics, Inc. reported a net loss of $17.6 million for the quarter ended March 31, 2026, as it continues investing in its GeneTAC small-molecule pipeline. Research and development expenses were $14.4 million and general and administrative expenses were $5.3 million.
The company ended the quarter with $222.8 million in cash, cash equivalents and investment securities, which it believes will fund operations for more than 12 months. Design also raised $19.9 million of net proceeds by selling 2,006,550 shares through its at-the-market program. Key programs include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy and DT-818 for myotonic dystrophy type-1, with multiple clinical readouts anticipated from 2026 onward.
Design Therapeutics, Inc. reported first quarter 2026 results and highlighted progress across its GeneTAC® pipeline. The company posted a net loss of $17.6 million for the quarter, with research and development expenses of $14.4 million and general and administrative expenses of $5.3 million.
Cash, cash equivalents and investment securities totaled $222.8 million as of March 31, 2026, which Design expects to fund planned operations into 2029. The RESTORE-FA Phase 1/2 trial of DT-216P2 in Friedreich ataxia is ongoing, with frataxin biomarker data expected in the second half of 2026.
Additional programs include a Phase 2 biomarker trial of DT-168 in Fuchs endothelial corneal dystrophy with data anticipated in the second half of 2026, and a Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type-1 expected to begin dosing in the first half of 2026, with results anticipated in 2027. The company also appointed David Shapiro, M.D., to its board of directors to strengthen clinical and regulatory expertise.
Design Therapeutics, Inc. is holding its 2026 virtual annual meeting of stockholders on June 9, 2026 at 8:00 a.m. Pacific Time. Stockholders of record as of April 14, 2026, when 62,441,429 shares of common stock were outstanding, may attend and vote.
Stockholders will vote on electing one Class II director, Simeon George, M.D., to a three-year term ending at the 2029 annual meeting and on ratifying Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board recommends voting in favor of both proposals.
The proxy statement also outlines board structure and independence, committee responsibilities, anti-hedging and anti-pledging policies, major stockholders’ ownership, and detailed 2025 compensation for key executives, including salary, cash bonuses and stock option awards.
Design Therapeutics director David Shapiro received new stock option awards, increasing his potential equity stake without any open-market trading. On March 31, 2026, he was granted options for 60,000 shares of common stock at an exercise price of $10.64 per share, expiring March 30, 2036. These options vest in equal monthly installments over 36 months following March 31, 2026. He also received a separate option for 7,500 shares at the same $10.64 exercise price, expiring March 30, 2036, vesting in equal monthly installments over 12 months following March 31, 2026. Both grants are reported as direct ownership and represent compensation awards rather than share purchases or sales.
Design Therapeutics, Inc. filed a Form 3 insider report identifying David Shapiro as a director of the company. The provided data shows no reportable transactions or holdings, indicating this filing serves only to register his status as a reporting person.